Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Bio-Techne Corporation (TECH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
362.77-7.29 (-1.97%)
At close: 04:00PM EDT
362.77 0.00 (0.00%)
After hours: 04:41PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Gap Down

Gap Down

Previous Close370.06
Open365.95
Bid145.54 x 800
Ask582.12 x 1000
Day's Range361.20 - 370.25
52 Week Range318.07 - 543.85
Volume152,210
Avg. Volume228,250
Market Cap14.233B
Beta (5Y Monthly)1.22
PE Ratio (TTM)54.72
EPS (TTM)6.63
Earnings DateOct 31, 2022 - Nov 04, 2022
Forward Dividend & Yield1.28 (0.35%)
Ex-Dividend DateAug 12, 2022
1y Target Est485.26
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
35% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for TECH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Bio-Techne Corp
    Analyst Report: Bio-Techne CorporationBased in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
    Rating
    Fair Value
    Economic Moat
    10 days agoMorningstar
View more
Advertisement
Advertisement